Clinical Trial Update: Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating isatuximab plus cemiplimab in advanced malignancies (prostate cancer and non-small cell lung cancer) has terminated with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Prostate Cancer

Drugs mentioned

• Cemiplimab (cemiplimab)
• Isatuximab (isatuximab)

Snippet

Sponsor: Sanofi | Conditions: Prostate Cancer, Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-05-16